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A recent malaria ep idemic in th e M cnoreh Hills of Ce ntral java has increased conce rn abo ut the re-e me rgence
of endemic m alaria on j ava, whic h th rea ten s the islan d 's 120 million res iden ts. A 2R-uay, in-vivo test of the
efficacy oftreat me nt of malariu with ant irnalnrial drugs was con du cted among 167 village rs in the .\ \c no reh Hills.
1111." treatment s investiga ted . chloroq uine (e Q) and sulfa doxine- pyrimcthum ine (SP) , constit ute, respectively, th e
first- and second -line rrcarmcn rs for uncomplicated malaria in Indonesia. 'I111~ prevalence of malaria among 1389
residents screened prior to enroll ment was 3.l% . Treatm en t outcomes were assessed by micros copical diagnoses,
peR-based confi rmation of the di agn oses, me asu reme nt or the whole-blo od conce nt rations of CQ and descth yl-
chloroquine (DCQ) , and ide ntifica tion of the Plasmodium [alc iparunt genoty pes. The 28~<by cumulative incidences
of the ra peutic failure for CQ and SP were, respec tively, ·17')1" ( N= 36) and 22% (N = ; 0) in the treat ment of
P. jalcipimt1l/, and 18'1. ( 0\'= 77) and 67 % ( X= 6) in the treatment o f P, 1'h."1.\:. Chloroquine was thus an
ineffective therapy for P. [alciparurn malaria, an d the presen ce of CQ- rcsistant P. V i1!aX and SP-rcs istant
P. j akip," "/tIIl will further comprom ise efforts to control resurgen t miliaria on j ava.
Java, which lies between Sumatra and Bali ,
is the most heavily populated island in the
Indonesian archipelago . Wide-spr ead hyp er-
and hole-endemic malaria occurred on Java
(Swellengrebcl et al. , 19 19; Schuurman and
Reprint requests to: j . D . M aguire .
E-mail : maguirc i J. (~ n'lmru2 .med . n<l\'y .mil ; fax: + 62 21
J2. ~ ·1;07 .
l 2002 T he Liverpool School of T ropica l M ed icine
DOl: IO.1 17Q100n H tlS021 250021 ! O
Schuurman-Tcn Bokkel Huinink, 1929) until
the 1950s. A malari a-eradicat ion ca mpaign
dominat ed by DDT sp raying was th en
successful in th e East an d West prov inces
of Java and brought malari a transmission
under con tr ol in the Cen tra l provin ce
(Atm osocd jono, 1994) . H owever, the cam-
paign did n ot elim ina te thc species of
mosquito that had transmi tt ed the malari al
656 .\ IAGUIRE ET AL.
pa ras ites. Habitats tha t suppo rt notorious
vectors such as A nopheles sundaicus, An.
maculatus, A ll. balabaceusis and Au. aconitus
still dominate the landscape, and j ava rem ains
highly receptive to endem ic malari a.
The malaria situati on on Java re mained
stab le from 1960 to about lCJ97. However ,
the tumultuous political, soc ial and eco-
no mic events that have occurred in Indonesia
over the past 5 years and the Asian eco nomic
crisis of 1997 devas ta ted budgets for malar ia
contro l. During thi s time, the incidence
of ma laria on Java has risen mar kedl y.
Altho ugh ra re before 199 7, outbreaks
invo lving thousands of people now occur
regu larly. T he ann ual pa rasi te incide nce
for Java inc reased 8-fo ld, from 0. 1 to 0.8
infec tions/ 1000 person-years, between 1996
and 2000 (Barcus et al. , 2002).
A recent malaria epidemic in the Men oreh
Hill s of Centra l Java was investigated by
Bar cus et al. (2002) . In the mo st badl y
affec ted area} the district of Purwo rcio, the
annua l para site incidence incre ased from five
[Q 48 infec tions/ IOOO pe rson-years between
1997 and 2000. The s tra tegy for attacking
th is ongoing epidemic includes plans for
mass ant ima larial drug administration (M DA)
in specific, high-risk areas. As it was unclear
how effec tive th e available ant imalarial
drugs were likely to be, the present clinical
eva luation of two therapies for the trea tme nt
of un complicated, P, [alcipurum and P. vivax
malaria in Purworejo was conducted .
SUBJECTS AND M ETHODS
S tu dy Location
T he study was ba sed in Purworei o district,
which lies at 07 43 '- 0 7' 46 'S and 110 05 '-
110 OTE, in the Central province of Java
(Fig.). The district has a population ofapproxi-
rnately 750,000, most of who m are engaged
in agricultu re. Three hab itats characterize
the landscape: ( I) a narrow coastal strip of
ma ngrove and swam p, with fish po nds ; (2) a
broad plain dominated by rice pa ddies; and
(3) the fore ste d and cu ltivated hills (F ig.).
The abundant rainfall (4000 rum/year) and
yea r-ro u nd temperatures ra ngi ng from
23-36 C create a warm and hu mid, tropi cal
climate. M ost human ma laria occ urs in the
hills, where the vectors A ll. mac ulatus and
A n, balabacensis breed in shady seepage pools
or rocky strea m beds (Ta kken and Kn ols,
1990) , Us ing d ata colle cted at government -
operated clinics as the result of passive
malaria surveillance, four villages in the dis -
trict were identified as high-risk communities
for malaria: Kaliharjo, Loano, N garan and
Ka ligono. Each of the se villages is loca ted
on steep hillsides in the cast of the di strict,
at 160- 780 m above sea level.
Stu dy S u bjects and E n rollment
Potential subjects were identified du rin g
mass scree nings conducted, in the four high-
risk villages, at the request of local health
authorities. Overall, 1389 residents (7% of the
combined po pulat ion) prese nted for screen-
ing and provided fingerprick-blood samples
for the preparat ion ofGicmsa-sraincd blood-
smears. After the sm ears were checked for
malarial pa rasites by micro scopical exam-
ination, all of those with slide-confirmed
malaria were offered standard antima larial
the rapy. Those who were aged ~ 5 years
and thick-smear-positive for asexual para-
sites ( > 40 asexual parasites/ul ) were invited
to enrol in the pre sent study, afte r provid ing
informed consent. The study protocol and
informed-consent procedures conformed to
the regula tions of the Repub lic of Ind onesia
and U.S, N avy govern ing th e use of human
subjects in medical research and were reviewed
and approved by all convening inst itutiona l
review boards. A full clinica l assess ment,
including medical histo ry, physica l exa m-
ina tion and basic laboratory testing, was
completed to de termine eligibility. Excl usion
criteria included complicated malaria (W H O,
2000), a history of antimalarial the rapy in
the past week, history of allergy or adverse
reac tion to chloroquine (CQ) or sulfa-
doxine-pyrimcthaminc (SP) , pregnancy, or
unwillingness to participate.
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Java Sea
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Kalih arjo
West Java
Indian Ocean
FIG. Map of Java showing the loc ation of Pu rwore]o district. Th e inset shows the district in more detail. with
the locutions of the four study villages and the sub-districts in which hills (.), low paddy ( ) and coastal plains
( ::J) form the predominant feature of the terrain.
In-vivo Test
Assignment to the various treatment arms
was based on the resul ts of th e microscopical
di agn oses and th e locall y applied th erapeutic
practices. Although Loano village followed
the guideli nes of the Indonesian Mini stry of
H ealth (IM oH) , in usin g C Q as first-line
therapy for uncomplicated, P. [a lciparum
malaria, the other three study villages had
ind epe nde ntly ado pted SP as the first- line
treatment. The treatm ent groups were there-
fore: ( I) CQ for P. falc iparum or mixed
P. oioaxlP. [alcipannn in Loan o; (2) C Q for
P. oiuax in all villages; (3) SP for P, fa kipannn
in all villages except Loan o; and (4) SP for
mixed P. uiuaxtl", fa lcipan un in all villages
except Loano.
Subjects in the two CQ-trcatmcnt groups
received directly observed doses of chloro-
quine diphosphate (Resochin t~; 150 rng base;
P. T . Bayer Indonesia, Jakarta) : 10 mg base/kg
on day 0, 10 mg base/kg on da y I , an d 5 mg
base/kg on da y 2. Subjects in th e two SP-
treatment groups received Fansidar" tablets
(500 mg sulfado xine/2 5 mg pyrimethamine;
Hollman La Roche Indonesia, Jakarta) as a
single dose (the tablets being broken int o
quarters so that a dose of about 25 mg sulfa-
doxine and 1.25 mg pyrimetha mine/kg could
be given ), Although the IM oH 's guideline s
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advoc ate a single do se uf <15 mg primaqu ine
base for P. [alciparum; as a transmission -
blocking measure, and five daily doses of
primaquine base ( 15 rug /day) against P. vnsax
relapse , primaquine tre atment was deferred
until the study endpoint. [As primaquine
has appreciable blood sc hizonticida l activiry
against P. viuax (Pukri ttayakarnee ct at.,
199-1), its use would have made it difficult
to gauge the therapeutic efficacy of CQ
against P. vivax.]
Su bjects were ac tive ly foll owed for 28
days, with bJoodsmears being made on days
0, 1, 2, 3,4, 7 , 11, l-l , 18 , 21 and 28 and
on any day a subject complained of illness .
Blood-blot specimens were obtained , for
estimation of whole-blood concentrations
of C Q and de sethylchloroquine (OCQ) by
HPLC, on da y a ( pre-t rea tment ), day 2 and
either day 28 or the day of recurrent para-
sitaernia. Blood-blots for DNA analysis were
collected on days 0, 7, 14, 21 and eith er 2R
or the day of recurrent parasitaemia . All the
samples for the blots were collected from
fingerpricks into heparinized, 1OO-~II micro-
capillary tubes and exp elled onto Whatm""
1':0. I filtcr paper (Whatman International,
M aid stone, U.K.) for dryin g and sto rage.
Subjects with persistent or rec urrent para-
sitae rnia during follow-up were treated,
according to the I~\oH ~s guide lines, with SP
(for P. falciparum after failure ofCQ therapy)
or quinine (e ither for P. [alciparnm after
failure of SP th erap y or for second-line
treatment of P. 1.'i~:ax) .
Laboratory ~\ethods
~CREEr-;I~(j
Pregnan cy was assessed by the semi-
quantitative measurement of urinary hum an
cho rionic gonad otropin , using a comme rcial
kit (Urin e h CG Test Pack Plus; Abbott
Labora tories, Abb ott Par k. IL). Haemo-
globin levels were determined for all of the
study subjec ts, in a Leica Hb-Mctcr (Lc ica,
Buffalo , NY).
," ICROSCOPY
Bloodsm cars were examined by expert-
certified microscopi sts. A thick smear was
only declared neg ative if one or no asex ual-
stage parasites had been seen aft er 200 fields
of th e smear had be en checked at x 1000.
A positive reading required at least two
unambi guous asex ual parasites in 200 fields .
Asexu al parasites were counted against 200
leucocytes in th e thick smear and the counts
co nverted to parasites /ttl, assuming each
subject had 8000 leucocytes/ul.
OETF.CTIN"G J!':FECT IOSS USING peR
' Ibe single-stranded ribosomal R.'1A (ssrRNA)
of any malarial parasites present in a dried
blood-blot was am plified by PCR, both to
cunfinn the microscopical diagnoses and to
detect any microscopically subparcn t para-
sita ernias. DNA was extracted directly from
the blot s of blood co llec ted on da y a and
day 28 or [he day of recurrent purasitaernia,
using Chelcx'" 100 5f}:, resin (Bio-Rad
Lab urutories, Hercules, CA) in distilled
water. Samples were incub at ed for 20 min
in a heat block at 56 C, followed by 8 mi n
in a heat block at 100 C. T he species-
specific variant domains of the malarial
ssrRJ"J'A genes were then amplified (Kimura
ct al. 199 7) . \X'hen the results of the micro-
scopical and PeR-based diagnoses were dis-
co rdant, two microscopists who were blinded
to the result of the PC R-based diagnosis
re-exa mined the relevant smear. The final
res ult was taken to be that of the PCR and
at least one microscopist or, when they con-
curred, [hat of both microscopists (even if
this co nflicted with the PCR result ) .
GF.~On~PJKr.
T he blots of blood co llected from those
infected with P. falcipannn who had recur-
rent parasitaemia were used to disting uish
recrudescences from re-infection s. 111e para-
sites in the blots of the blood sam ples
co llec ted on day 0 and [he day of the recur-
rent parasitaem ia were gcnorypcd on the
basis of their me rozoite surface protcin-Z
('\ \SP-2) gene' (Felger , I al. , 1993).
HPLC Al':ALYSES
Blots of blood ( 100 pi) co llected on da y 0,
d ay 2, and da y 28 or the da y of recurrent
par asit uem ia were used [ 0 determ ine th e
who le- bloo d conce ntrat io ns of CQ and
D CQ by I-lPLC (.\ l ode! 2700; Bio- Rad,
Richmond, CAl . HPLC was also used to
determine the sul fadoxinc and p~vrirn ctharnine
concent rations in the plasm a from blood
sam ples collected on the d ays of rec urren t
parasiracrnia (Ed stein ,I al., 199 1) ; the
lower limits of th ese quant ifications were
100 ng.rnl for sulfadoxine and 5 ng/ml for
pyrimethamine.
Data An a lysis
T he m ain aim of the presen t stu dy was to
estima te the risk of therapeutic failure after
supe rvised trea tment with sta ndard anti-
malarials - specifically, [0 es timate the
risk of ther apeutic failure whe n treating
P. [alciparum or P. Vi7XIX w ith C Q and whe n
treating P. [alcipannn with SP. Subiects with
both recurren t pa rasit acmia and day-Z CQ +
DCQ blood concentrations of < 305 ng /rnl
( i.c. more than 1 S. D. below the me an for the
study population) were excluded (CQ + D CQ
concent rations below this threshold were con-
sidered consistent with inadequate absorption,
since compliance was ens ur ed) . Subjects
who cleared the ir parasita cmias b ur had
C Q + n CQ concentra t ions cons istent with
ina de quate absorption were not exclude d
because) in these cases, C Q sens itivity was
established by cl inica l cure despite the d rug
conce n trations. Subjects lost to follow-up or
withdrawn because they were trea te d for
intercurrent infection (with a Plasmodium
species other than the one presen t on day 0)
before the end of the follow-up period con-
tributed to the person-time at risk up to th e
point of th eir loss /withdrawal. Subjects with
mismatch ed ~\ lSP2 genotypes at enrollme nt
and recurrence were classified as rc- infccted
and treat ed ana lytically as wi thd raw.a ls.
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Subjects wh o developed recurrent P. t'WtlX
whil e they had C Q + D CQ concent ra t ions
of < 100 ng/m l were also counted as with-
drawals, because their recurrent purasitacmias
cou ld have been the result of relapse or
re-infection. The rati onale for interp reting
the resul ts of th e in-vivo tests for C Q agai nst
1'. viuo» is derailed elsew here (Baird el £II.,
1997a). C um ulative inci dence, or risk, of
therapeutic failure was estim ated by act uarial
( life-table) ana lysis.
RESULTS
Screening
Among 1389 villagers screened, -l52 (33%)
had slide-confirmed malaria. T he village
p reva lence of ma larial in fec tion ranged
from 26'}{, to 38 % . Overall, 37 %, 57 % and
6'% of the in fec tions dete cted were pure
1'. [a lcipurnm, p ure P. viuax and mixed
P. [alcipanuulP. vioax, respectively. Among
th e 4 52 pa rasitaernics, 173 (38% ) co m-
plaincd of illness co ns iste nt with malaria.
Demographic, Clinical and
Parasitological Parameters at
E n rollmen t
Ove rall, 167 su bjects were enrolled in
the treatment trial: 73 with pure P. '( '; '(hIX
infections, 7 --l with pure P. fakiparum,
an d 20 with mixed P. [alcipartnnlP, cicux
infec tions . Table I lists the demographic,
clinical and pa ras ito log ica l cha racteris tics of
th e subjects by treatment group . The rati o
of female to ma le subjects was 1.3: I . The
preva lence of sp lenomegaly was consistent
with hype r-e ndemic malaria . Splenomegaly
was observed in most of the ad ults and all
of the children enrolled, alt hough only 13
su bjects were aged < 10 years. Of the 9-i
subjects infected with P. [alciparum (in
p ure or mixed infections), 3 1 (331Y..) were
feb rile and 60 (M%) were symptomatic
(with headache, ma laise) myalgia. arthralgia ,
abdominal pain, fever and/or chi lls) . Of the
93 subjects with P. uirax ( in pure or mixed
infect ion s) , 15 (16%1) \\'CT~ feb rile an d 45
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(4 8%) co mplained of symptoms. In general,
the P. [alciparum parasite densities were
greater than th ose of P. vivax; the only
excep tion was in the mixed infections in
those treated with CQ , where the P. viuax
parasite densities were greater than the
P. falciparum.
Drug C on ce ntrati o ns
Table 2 sum marizes the CQ + D CQ con-
centrations in the blood samples collected ,
from the subjects treated with CQ, on day
o ( pre-treatm ent) , da y 2 and the day of
recurrent para sitaernia . •Mixed infections are
included in both the P. falciparum and
P. ,(livax co lumns. Pre-treatment samples were
avai lab le for 38 and day-2 samples for 37 of
the 40 sub jects in fected with P. falciparum
and treated with CQ. Pre-treatment and
day-2 samples were available for 76 and
75, respectively, of the 87 individuals
with P. vivax who were treated with CQ.
CQ + DCQ co ncentrations were deter-
mined for all 44 subjects with rec urrent par a-
sitaernia during follow-up. Among those
tre ated with CQ, 4 2% ( 16/38) of the sub-
jects with P. fatcipanon and 37% (28176) of
those with P. oicax had detectable CQ +
DCQ concentrations prior to enrollment,
indicating self-administered CQ. The ove ra ll
me an (s.n.) day-2 CQ + D CQ concentration
for all those treated with CQ (regardless
of parasit e species) was 667 (362) ngim l.
Although two of the sub jects infected with
P. [u lcipannn and five of those infected with
P. uiuax had day-2 concentrations far below
normal, only one of these seve n subjects
(who had a P. vivax infection) developed a
recurrent parasita ernia and was therefore
excluded from the estima tio n of therapeutic
efficacy, on the presumption of inadequate
C Q ab sorption.
Am ong th e 54 subjects treated for
1'. [a lcipannn with SP, only 22 da y-O ( pre-
treatment ) plasma samples \v·ere available
for measurement of sulfadoxine and pyri-
methamine concentrations. Six (2 70/0) of
these 22 had det ectable sulfadoxine and
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pyrimethamine conce ntrations, indica ting
recent use of SP prior to enrollment. Plasma
samples from the day of rec urrent para-
sitacrnia were available from six of the nine
subjects who experienced SP therapeutic
failure (T able 3) . With th e except ion of one
subject with undetectable pyrimethamine
conce ntrations, all six subjects had detect-
ab le concentrations of both drugs on the day
of recurren ce, with mean concentrations of
28 ug sulfadoxine and 48 ng pyrimethamine/
ml, respectively .
Post-therapeutic Clin ica l Course of
P. fa lciparurn Malaria
Clinical co urse did nor differ between treat-
ment groups. M ost of th e physical com-
plai nts reported at enrollme nt had resolved
by day 4 , whether those affected had been
treated with CQ or SP. The numbers of
com plaints on da y 4 were only 3 1% (C Q)
and 38 % (SP) of those observed on day o.
Differences in the resolut ion of specific co m-
plaints between the two main treatment
groups (i.e. C Q t'. SP) were not statistically
significant, with P-values between 0.2 and
0.98 (d ata not shown) . Fever ( i.e. an axillary
temperature > 37.5"C) resolved by day 2
among those treated with CQ but not until
day 3 am ong those treated with SP ( P> 0.05).
Outcomes of the In-vivo Tests
Of the 40 subjec ts treat ed with CQ for
P. falcipanun, two were lost to follow-up after
day 0 or d ay I of the rapy. Of 22 recurrent,
same-species infections, four were excluded
from analysis because the day-of-recurrence
P. fa lciparum DNA co uld not be amp lified
for M SP-2 genoryping , leavin g 34 eva luable
infections. T hi rteen (38%) of these 34
co mpleted the test withou t recurrent para-
sitaernia, three (9%) developed intercurren t
P. 'l:i'l'ux during the post -therapeutic course,
and the remaining 18 (53%) developed
recurrent P. fakiparum infections during
follow-up . Based on MSP-2 genoryping,
most (14) of the recurrent P. [alcipannn
infections were identified as recrudescences
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TABLE 3. Plll.HUll HtlfadlJxillt! and pyrimethamine concen trations em til.· doly of M~IIm:1Zt Plasmodium falciparum
intecnon otter tr.",um.·1/l n'itll <l standard dose (If mljo1dtlXi".:-/'.vn·m"lhl11/1/lI/."
Age of subject Sex Il f subject Day of rec urrence Sulfudoxineurg-ml) Pyrimethamine (ng.ml)
11 " la ic II 1" .2 3R
IR Fema le II 27 .9 80
60 Fem ale II 67 .i 132
-1·1 .'\ \ale IR -12.7 13
R ,\ \ale 2 1 2.7 Un detectable
')5 Female 18 1·1.3 5
and the other four as re-infecti ons. T aking
all of the ide nt ifiab le con foundi ng factors
into co ns idera tion, the overa ll cum ulative
incidence of failure of CQ therapy for
un complicat ed P. [alciparnm was 47 %
Cr able 4).
Of th e 87 sub jects treated with CQ for
P. -uiuax, nine were lost to follow- up between
day 0 and day 2 of therapy. Of 22 recurrent,
same-s pecies infections, one was excluded
from analysis because the corresponding day-Z
CQ + DCQ concent ration was < 30 5 ng /rnl,
TABU~~ . L~rL'-taM.: represemanon 0/ ,ilL' L'1II1W!<Uir:L' il1dJ':IICL' L1/ Ilta"pL'll1if f a ilure ,JfTn'bwab!L' II' drug resistance
aJIIV/l.t! th.. s " N,'ct.~ treated mth chlo roquine ,lr SII!jl1dll:d"c- py n"m.:tltlJm illt.' ·
S ubiects infected wi th Plas modillm fukip<111ml Subicct.. infe cted with P. ;.:it'llX
Day S I n- IR e l l' s I w II( e ll'
TREAUIF.l\' \\HII ClJI .OROQlTISE
0 10 0 6 0 0 87 0 10 0 0
2 30 () 0 II 0 77 0 0 0 0
31 2 0 0 .06 0.06 77 0 I 0 0
7 32 0 0.0 3 0. 09 76
"
2 0 0
II 31 I 0 .03 0 .12: , ·1 0 0 0
II .:!<I 2 2 O.Oi H.tH 73 I 0. 01 0.0 1
IR .:! ; 5 2 0 .2 1 o.as 0"
"
5 0 0.01
11 18 2 0 .06 0. 39 M 6 2 0. 10 0. 1 1
28 I> 2 0 0 .1 3 ll. H % , 10 O.OR 0. 18
TREATt.\E KT wrru M.a.fAIHlXIl':E- PYR TMf.TlM..\ II:>O:E
o 5 1 () ·1 0 0 6 0 0 0 0
2 'in 0 I' 0 o 0 o o 0 0
I 50 () I 0 0 6 I' 0 o o
7 ·19 I 2 n.02 0,02 (, I o 0 . 17 0.17
II 4h 3 2 0 .07 O.Oq s I () 0 .20 0 .33
I I ·11 0 2 0 0.09 I
" "
0 0 .33
I R 39 ) 2 0 .03 0 . 1 1 .) I 0 D,:!'> 0 .'50
2 ) 30 I 2 0 .03 0 . 1·1 3 () () 0 0 .'50
2S 13 3 0 .09 0 .:!2 3 ) 0 0 .33 0 .b7
"ln thi s table. S represents th e number o f subjects •.H risk of therapeutic failure at the stan o f inter....al , 1 me
number of cases of therapeutic failure during: the interval, anJ t V th e number of subjects withdrawn from the test
during th e inter....al (be ca use ofexcl us ion from the analys is, loss to follow-up after previous bloodsmear, intercurrent
infe ctio n ....-irh alternate species, re-infection with a ditferem genotype of P. jlJli:lpanm, or evidence of relapse/
rc...infection bv P. 1.';1.'<1.\", bas ed on the blood concentrations nf chloroquine - dcsythlchloroquine on the day of
the recurrent para sitaemia). m, is the- risk of therapeutic failure in me: interval, ca lculated as i llS - (. ':'/2)1. and
e l F the cu mula tive incidence of thcrapeunc failure, calculated as I - [(I - IR,,)( I - e lF,. I»)' where Ik, is the
IR in th e curr en t inter-..al and e lF,. I is the cumulative inci de nce up 10 the previous interval.
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leaving 77 eva lua ble in fections. Forty-two
(55%) of th ese 77 com p leted the test
without rec urre nt par asit aernia, 12 (1 6lYi,)
develo ped intercurrent P. [alcipurum (and
contrib uted pe rson-time: at risk up to the day
of that diagn osis) and two (3%1) were lost to
follow-up when aparasitae rnic (one after day
7 and th e othe r after day 14). The remain-
ing 2 1 subjects (27%) d evelop ed recurrent
P. uiuax at some time during follow- up .
Eleven of the recurrent P. ciuax infections
were conside red to be recru des cent (resistant ),
based on concurrent C Q + DCQ concen-
trati ons th at were > 100 ng/m l, The other
10 recu rrent P. vivax infections, a ll of which
occurre d on day 28 of follow-up, were
designated as relapses or re- infections because
the corresponding day-of-recurre nce concen-
trations of C Q + D CQ were < 100 nglmJ.
Taking all of the ide ntified con founding
factors into cons ideration, the overall cum u-
lative incid ence of failure of CQ therapy for
un complicated I '. uioax was 18% (T able 4).
Fifty-four subjects we re treated with SP
for P. fa lciparum infections. O f 17 recurre nt,
same-species infections, four were excluded
from the analysis because the day-O or day-
of-recurre nc e P. [alciparu m D NA could not
be amplified for MSP-2 genoryping, leaving
50 evaluable infec tions. Twenty-nine (58 %)
of the se 50 completed the test without rec ur-
rent pa rasitaemia, seven (14 %) developed
in terc u rr en t P. vivax (and cont ribu ted
person-time at risk up to the da y of tha t
diagnosis), and one (2%) was lost to follow-
up after day -1 . The rem aining 13 sub jects
(26%) develop ed recurrent P. fa lcipurum at
some time during follow -up . Of these 13,
nine were considered recru descent and four
as new infection s, ba sed on the results of
MSP-2 genoryping, The overall cum ulative
incidence offailure of SP therapy for uncom-
plicated P. [alcipa rum was therefore 22%
(Table 4).
O f th e six sub jec ts treated with SP for
P. v ivax, none was lo st to follow-up or
excluded fro m ana lysis . T wo of the six
completed the test \v·itho ur recu rre nt par a-
sitaemia bu t the remaining four sub jects pre-
scnted with recurrent pa ras itaemia (one each
on days 7, I I , 18 and 28 ) yield ing a cru de
estima te of risk of SP the rape utic failure of
67'% (Table 4 ) .
Com pariso n b e tw een the
Micr oscopica l a nd peR-based
Diagnoses
The PeR-based am plification was success-
ful for 163 of the 167 su bjects enrolled -
sam ples were not avai lab le for amplificatio n
fro m two subjects with pure P. falc iparum
infecti on and one with a mixed P. [alcipannnt
P. uiuax infect ion, and no prod uct was
am plified fro m a sample collected from a
subject wi th a pure P. oirox infection . All 38
sub jects wh o were classified as therapeutic
failures (1 5 subjec ts with 1'. uioax and 23
with 1'. falciparum) provided day-of-failure
samples that were successfully evalua ted by
PCR. When the resu lts from the PCR were
com pared with those of the micr oscopical
diagnosis (Table 5), the overall sens itivity of
either method , co mpared with the other,
for detectin g the appropriate species with
perfect concorda nce was 59 (%.
DISC USSION
The present results indicate that resist an ce
to CQ in both P. [alciparum and P. uicax,
and to 51' in P. falciparnm, is common in
the Menoreh H ills of Central Java . Almost
one in every two (47%) of the P. [a kipurnm
infections in this are a is res istan t to CQ,
22% of the P. [alcipannn infec tions ar c
resi stant to SP, and 18% of the P. vivax
are resistant to CQ . T hese findings corro-
borate those of sim ilar studies elsewhere in
Indones ia (Smrkovski ct ai., 1983; Baird el ol.,
1991 , 1997b; FryauIf er al., 1997, 1998a , b)
and support the use of SP as the first-line
therapeutic choice again st P. [alcipa runr
malari a in Java and the retention of CQ as
the first-line treatment for P. riuax malaria.
H owever, {his approach is serio usly limited
where spec ies determination may be unreliable
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TA BLE 5. ClIIllp..nison b..'f'Wc' r?" th e rem/IS In",t tlu PCR-bd5r:d ass<l)' a nd Ih~ CQrT,:spol1dillg rendu of the microsct,pical
examina tion of bIOtJ(hm~aN - in eacli test, blood samplr:s col lected prc-treutmau (day 0) el f 01' ,IIl d<1y (if therapeutic
failure were clr,','k ,'J f or Plasmod ium falciparu m ( P f ) and P. vivax ( 1'-0)
N o. (If positive samples in the PeR-based assay
Day 0 Day of th era peutic failu re
Pf Pv Pf ~ Pv Pf Pv PC+ Pv
so. OF SA.\IPLES FOUl'\l) SMJ:::AR- I'O SITJ"E
Pf 50' 0 22 14' 0 6
p\, 5 28 - 39 0 10 ' 2
Pf .;. Pv 5 2 Ir 2 0 4'
• Concordant resu lt.
or unavailable, since misidentificati on of a
P. [alciparum or mixed P. faldpanuntl>: oiuax
infection as a pure infectio n with 1'. v ivax
would the n often resul t in ineffective therapy.
A common first-line therapy effective against
both P. fakiparum and P. uiuax need s to
be iden tified . Such a trea tment wo uld serve
a vita l strategic role in reg aining co ntro l of
ma la ria in Java .
The in-vivo test used in th e present study
represents a modificat ion of the standa rd,
28-day, 'extended ' field test (W H O , 1973),
the most important changes being in th e
recruitment criteria and follow-up . The pro-
cedures rec ommended by the World H ealth
Organizati on (\VHO) we re not designed for
well -equipped research teams on temporary
assignment but for the staff of rural clinic s,
using routinely available resources (W HO,
197 3). The W HO's protocol call s for passive
methods of subject identification and follow-
up. In contrast, a researc h team often
possesses both the means and motivation
(in terms of the economic usc of effort
and inves ted time and reso urces) for active
recruitmen t and follow -up. As the current
Mcnorch-Hills epidemic began, in an area
wh ere the re had been no routine passive
surveilla nce of drug efficacy, the local
health authori ties urgently required definitive
information on the th erapeut ic efficacy of
the antimalarial drugs avai lab le to them. A
research team - that co uld ob tai n the
required informa tio n with a min ima l inves t-
me nt in time an d resources - was therefore
dispa tched from th e U.S. N aval Medical
Research Unit in Jakart a.
The WHO 's method may be co nfo unded
by factors such as drug absorption , diagnostic
sens itivity, and an inabi lity to disting uish
recrudescence from re-infection an d relap se.
In th e p resent study, the issue of drug
absorption wa s specifica lly addresse d by
employing HPLC to determ ine b lood con-
ccnr rations of CQ , D C Q, su lfadoxine and
pyrimethamine. Confirmation of the presence ,
at the time of rec urrent parasitaernia, of
CQ + DCQ concentra tions that exceeded
the minimal effective concentration (l\l EC)
provides definitive evidence of resistance.
The MEC of C Q agains t (CQ -sensitive)
P. vivax has been estimated to be 15 mglml
plasma (ro ughly 120 ng/rnl whole blood;
Berliner ec al., 1948), 90 ng/ml wh ole blood
(Rombo et al., 1986) and , in Indonesia,
100 ng/rnl whole blood (Baird ct al. , 1997 a) .
Although the M E C for SP is not known with
certainty, concentrations of sulfadoxinc and
pyrimethamine were measured on the day
of recurrence in those treated with SP in the
present study, to assess th e likel ihood that
absorption of th ese drugs had been nonna!.
Rased on eliminat ion half-lives ofabout 180 h
for su lfadoxine and 90 h for pyrimethamine
(Weidekam m et al., 1982), five of the six
su bjects who failed SP treatment had drug
concentrations consisten t with no rmal absorp-
tion . Although inter-ind ividual varia tio ns in
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the pla sm a concentrations of sulfadoxine
and pyrimethamine may be wide, the drug
concentra tions measured during the recurrent
infections in the pre sent stu dy were com-
parable with the values reponed by others
(Sarikabuthi <1 al., 198 8; Hcllgrcn el al.,
1990) . 11,e abi lity to m easure drug concen-
tra tions in subjects may prevent inappropriate
inclusion of those with inadequate absorp-
tion as treatment failures, thereby minimizing
the over-est imation of treatment failure.
There is d earl y a need for further inve sti-
gations of th e MEC for sulfadoxine and
pyrimethamine.
The W HO's method (W H O, 1973 )
ma y also be confounded by low diagnost ic
sens itivity and the inability to di stinguish
recrudescence from re-infection and relapse .
In the present study, relatively sophistica ted
laborato ry tests were cond ucted [0 support
the cla ssification of infections as resistant or
sens itive. These inclu d ed the PCR-based
detection of infectio n, and the 1\ 15 1'-2 -
ba sed genoryping of parasites, [0 di stinguish
re-infecti on from recrudescence in th ose
infected with P. [alciparum. Several rep orts
support thi s application (Babiker <1 al.• 1994 ;
Ohrt et al., 199 7; Bro ckman er al. , 1999),
wh ich allows a m ore accura te estimate of
the risk of th erapeutic failure becau se of
resistance than would o therwise be possible.
The PCR-based di agnosis of malari a in
clinica l se ttings presents many uncertainties .
The sensitivity and specificity of such diagnosis
are difficult to estimate against a micro-
scopica l standa rd that is almost cert ain ly
less ac curate . T he frequencies of false-
positive and false-negative diagnoses remain
unknown . M oreover, sta ndard protocols and
sets of reagents manufactured for clinical use
are no t yet available. The results of some
studies indica te a poor co rre latio n between
th e results of a PCR-based assay and of
microscopy (Gaye r!l ul. , 1999; Tham et al.,
199 9) . Cryptic P. falciparum in fecti ons m ay
often accom pa ny infection s d iagnosed as
pure P. 1!i'1.'ax and only become detectable by
microscopy after CQ treatment (Mason et al.,
200 1; M ayx ay et al., 200 1; Siripoon a al.,
2002). In the- present stu dy, P. fukipun nn was
some tim es detected, after C Q treatment, in
sub jects wh o appea red (by m icro scopy) to
have had pure P. cieax infection s at enroll-
ment. H owever, thi s occurred primari ly in
subjects who were found to have had the
ss rRN A of both P. [alciparum and 1'. vivax
in their blo od at enro llm ent, indicating
th at they had (m icroscop ically) cryptic
P. [alcipannn at th at time . The clinical
significance of d iscordant PCRJmicroscop y
diagn oses remains un clear, and the possi-
bility th at the re are false-posi tives among
the PCR res ults, for which no probability
has been est imated, must be co nside red . In
the present study, therefore, use of p eR
was limited to affirming th e microscopical
d iagnoses, and a positive PCR result was not
cons ide red evidence of parasit acmia unl ess
parusitacmia was detected , in the corres-
ponding bloodsrnear, by at least one
microscopist.
The WHO's pro tocol requires a mini-
mum parasit aem ia of I000 para sites/ul for
1'. fulciparum, Alth ough the majority of sym p-
to matic malaria cas es repo n ing to clinics
have pa rasitae rnias above th is th reshold, most
people fo und to have malarial infec tions
during active case detecti on typically have
co nsiderably lower parasite counts. In the
presen t study, for exa mple , th e median
parasi te co unt for P. [alciparum at en roll -
ment was only 840/pl. Excl udi ng sub jects
with pa ras ite de ns ities below the \X'HO's
thresho ld not only compromi ses the efficiency
of recruitment but may also introduce <1
profound sample bias. If th ose with para-
sitae mias of at least 1000 para sites/ul
comprise only a minori ty of all those with
parasit acrn ia, they clea rly do not represent a
suitable, representa t ive group for estimating
th e community-wide risk of th era pe utic
failure.
T he present es timates of the risk of thera-
peu tic failure attributable to resistance arc
th e resul ts of a systematic effo rt to minim ize
class ification errors, by usin g the relatively
sophis tica ted lab oratory techniq ues available
to th e research tea m. The es tima tes indi cate
an inadequate therapeu tic response to CQ,
and a modestly efficac ious respo nse to SP
among the P. fo lcipannn in fect ion s in vest i-
gated. A combination of CQ and SP recentl y
showed > 90 %, efficacy again st un com-
plicated P. [alcinannn malaria in the Ce ntral
province of j ava (J . K . Baird, un pub!. obs.),
and this combination may rep resent the
mo st appropriate treatment until o ther com-
bined therapies arc evaluated and licen sed
in Indonesia. Resistance to CQ by P. uiuax
occurred in 18% of th e infections evaluated
in Purworcjo ( present stud y). This repre-
sen ts the first confirmation of CQ-resista nt
P. vivax ma laria on the island of Java . The
m ust important problem with maintain ing
C Q as first -line therapy for P. uiuas malaria
is not th e 20 % risk of therapeutic failure but
rather the rnuch higher risk of using CQ
against misdiagnosed P. fatcipanon mala ria
and th e predictably po or outcome in that
event. A safe and effective trea tmen t for both
P. falc ipa runt and P. ciuax malaria is the re-
fore vitally needed in areas such as the
M cn oreh Hill s of Central j ava .
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